In a recent systematic review of 43 studies and 5113 patients with BRPC and no known metastatic disease, the pooled detection rates for PSMA radiotracers in patients with BRPC after definitive therapy and a PSA level of <0.5, 0.5 to 0.9 ng/mL, 1.0 to 1.9 ng/mL, and ≥2 ng/mL were 45%, 61%, 78%, and 94%, respectively [15]. The gene discussed is FOLH1; the disease is metastatic neoplasm.